Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Insulin resistance, clinically defined as the inability of insulin to increase glucose uptake and utilization, has been found to be associated with the progression of Alzheimer disease (AD). Indeed, postmortem AD brain shows all the signs of insulin resistance including: (i) reduced brain insulin receptor (IR) sensitivity, (ii) hypophosphorylation of the insulin receptor and downstream second messengers such as IRS-1, and (iii) attenuated insulin and insulin growth factor (IGF)-1 receptor expression. However, the exact mechanisms driving insulin resistance have not been completely elucidated. Quite recently, the levels of the peripheral inducible isoform of heme oxygenase (HO-1), a well-known protein up-regulated during cell stress response, were proposed to be among the strongest positive predictors of metabolic disease, including insulin resistance. Because our group previously reported on levels, activation state and oxidative stress-induced post-translational modifications of HO-1 in AD brain and our ongoing studies to better elucidate the role of HO-1 in insulin resistance-associated AD pathology, the aim of this review is to provide reader with a critical analysis on new aspects of the interplay between HO-1 and insulin resistance and on how the available lines of evidence could be useful for further comprehension of processes in AD brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 2×
“on estimates from ADAMS, among people age 71 and older, 16% of women have AD and other dementias compared with 11% of men (Plassman et al., 2007; Seshadri et al., 1997).”
MethodTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 14×
“, 2012), hypophosphorylation of the insulin receptor and downstream second messengers such as IRS-1 (Steen et al., 2005; Talbot et al., 2012) and attenuated insulin and IGF-1 receptor expression (Steen et al.”
BackgroundInfluentialThe enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.
Tenhunen, R., Marver, H. S., & Schmid, R. (1968) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.61.2.748 · Cited by 1,803
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 12×
“, 2012) and attenuated insulin and IGF-1 receptor expression (Steen et al., 2005).”
BackgroundInfluentialNitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543 · cited 2×
“, 2010), synthesis of nitric oxide (NO), which in turn plays a role in learning and memory processes (Calabrese et al., 2007); and (ii) the mitogen-activated protein kinase (MAPK) cascade, which is responsible both for the induction of several genes required for neuronal and synapse growth, maintenance and repair proc…”
BackgroundSelf-citationEvidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Self-citationHensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S. P., Wu, J. F., Carney, J. M., et al. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052146.x · Cited by 779 · cited 2×
“Because of the role of oxidative stress in AD pathology onset and progression (Butterfield et al., 2001; Di Domenico et al., 2011; Halliwell, 2006; Hensley et al., 1995; Lovell et al., 2001; Mark et al., 1997; Markesbery, 1997; Smith et al., 1994, 1997), most of the studies conducted in the past…”
BackgroundResultSelf-citationBrain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748 · cited 5×
“…risk of heart disease, stroke, obesity, diabetes and AD (Butterfield et al., 2014a; Craft, 2005; Craft et al., 1998; De Felice, 2013; de la Monte, 2009; Frolich et al., 1998; Hoyer, 2002; Molina et al., 2002a; Moreira, 2012; Shin et al., 2013), a wide literature described the involvement of HO in…”
BackgroundInfluentialRivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 2×
“Indeed, AD patients show reduced brain insulin receptor sensitivity (Rivera et al., 2005; Talbot et al., 2012), hypophosphorylation of the insulin receptor and downstream second messengers such as IRS-1 (Steen et al.”
Background
Cited by
Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 495
Butterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403
Self-citationde la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Mouse models of Alzheimer’s disease
Esquerda-Canals, G., Montoliu-Gaya, L., Güell-Bosch, J., & Villegas, S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170045 · Cited by 288
“Specifically, insulin resistance and heme oxygenase-1 protein levels are increased in the brains of AD subjects [23], whereas glucose transporter proteins, insulin receptors, and other components of the insulin signaling pathway have been found to be reduced in some AD patients [24].”
Clinical development of curcumin in neurodegenerative disease
Hu, S., Maiti, P., Ma, Q., Zuo, X., Jones, M. R., Cole, G. M., & Frautschy, S. A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1044981 · Cited by 179
Metadata
- Authors
- Barone, E., & Butterfield, D. A.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 84
- Pages
- 69-77
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2075508254
- Cited by
- 30
- References
- 27
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel? https://app.cochat.ai/papers/10.1016/j.nbd.2015.02.013
- The paper
- Barone, E., & Butterfield, D. A. (2015). Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel? Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2015.02.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.